KOSDAQBiotech & Pharma038530

Kbio Labs

₩2,115▲ 4.19%2026-11-18 close
Market Cap
₩11B
Turnover
₩20,704,780
Volume
9.9K
Shares out.
5.2M
PER
—
PBR
0.3×
EPS
-₩2,874
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Operating profit returns, but net loss widens under listing-rule pressure

Kbio Labs posted operating profit of KRW 1.13 billion in Q2 2026, but its net loss attributable to controlling shareholders widened to KRW 14.4 billion, and its market capitalization stayed below the KRW 20.0 billion listing-rule threshold for 25 consecutive trading days as of November 12, 2026.

  1. 1

    Revenue rose 14.1% to KRW 87.3 billion in 2025, extending two straight years of growth from the 2023 low, after KRW 76.5 billion in 2024 (up 180.0%).

  2. 2

    Q2 2026 revenue fell to KRW 5.88 billion, down 63.0% from the prior quarter and 71.7% year on year, and has declined for two straight quarters after the Q4 2025 peak.

  3. 3

    Según the August 14, 2026 company disclosure as reported by the press, first-half 2026 standalone revenue reached KRW 21.7 billion, up 28% year on year, with operating profit of KRW 300 million.

  4. 4

    Q2 2026 operating profit was KRW 1.13 billion, yet the net loss attributable to controlling shareholders was KRW 14.4 billion; the non-operating items behind this gap are the key point to verify next.

  5. 5

    The net loss attributable to controlling shareholders over the last four quarters (Q3 2025 to Q2 2026) totals KRW 14.9 billion.

02

Business structure

Kbio Labs centers on a bio distribution business that supplies laboratory reagents and scientific equipment to universities, hospitals and research institutes, according to the company's own materials.

In November 2021 it took over the distribution division of a Korean biotech firm and has continued the bio distribution business since. It discontinued its fashion business in April 2023 after transferring a fashion brand. In March 2026 the company changed its name to KBIO LABS Inc.

Based on a third-party tally of Q1 2026 revenue, bio distribution accounts for about 60% of sales and ICT about 40%. A Daejeon branch was established in January 2025, and in its first-half 2026 results explanation the company cited repeat purchases by existing customers and the Daejeon branch's sales as growth drivers.

Its largest shareholder holds a stake in the 40% range, and in July 2026 the company carried out a KRW 2.0 billion capital increase targeting that shareholder. Competition in distribution depends on securing customers and supply terms.

Direct comparison with large peers such as Samsung Biologics or Celltrion is limited because their models center on manufacturing and development. Details of the ICT segment's products and amounts should be checked in the segment notes of the periodic filing.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q2₩20.8B₩9,281,3370.0%
2025Q3₩17.6B-₩100M−0.7%
2025Q4₩28.4B₩1.3B4.6%
2026Q1₩15.9B-₩800M−5.1%
2026Q2₩5.9B₩1.1B19.3%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩33.6B-₩200M-₩7.7B−0.5%−11.5%23.5%
2023₩27.3B-₩600M-₩12.7B−2.1%−20.0%11.4%
2024₩76.5B₩800M-₩6.8B1.0%−12.1%9.4%
2025₩87.3B₩1.5B-₩3.2B1.7%−6.0%16.2%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-18

04

Earnings analysis

Annual results show revenue expansion alongside a narrowing of losses. Revenue fell from KRW 33.6 billion in 2022 to KRW 27.3 billion in 2023 (down 18.8% year on year), then rose to KRW 76.5 billion in 2024 (up 180.0%) and KRW 87.3 billion in 2025 (up 14.1%), with 2025 the largest year of 2022 to 2025.

Operating results were an operating loss of KRW 153 million in 2022 and KRW 561 million in 2023, before an operating profit of KRW 793 million in 2024 and KRW 1.52 billion in 2025 (up 91.9%).

Operating margin was -0.5%, -2.1%, 1.0% and 1.7% for 2022 to 2025, so revenue growth has not translated into a large margin gain.

Net loss attributable to controlling shareholders was KRW 7.67 billion, KRW 12.7 billion, KRW 6.79 billion and KRW 3.2 billion for 2022 to 2025, a loss in each of those four years, with the loss narrowing in 2024 and 2025.

Net loss including non-controlling interests was KRW 5.04 billion in 2025, a different figure from the controlling-shareholder number. Operating cash flow went from KRW 3.78 billion in 2022 to -KRW 1.46 billion in 2023 and -KRW 119 million in 2024, before reaching KRW 8.2 billion in 2025.

At end-2025, total equity was KRW 102.3 billion, of which KRW 53.3 billion belonged to controlling shareholders, so non-controlling interests account for close to half of total equity. The debt ratio rose from 9.4% in 2024 to 16.2% in 2025.

Quarterly revenue was KRW 20.8 billion in Q2 2025, KRW 17.6 billion in Q3, a peak of KRW 28.4 billion in Q4, then KRW 15.9 billion in Q1 2026 and KRW 5.88 billion in Q2 2026.

Operating profit turned from a KRW 808 million loss in Q1 2026 to KRW 1.13 billion in Q2, but the KRW 14.4 billion net loss attributable to controlling shareholders in Q2 far exceeds the operating result, so the non-operating items behind it should be checked in the filing notes. The net loss attributable to controlling shareholders over the last four quarters totals KRW 14.9 billion.

05

Industry analysis

Distribution of laboratory reagents and scientific equipment moves with research and development budgets and experimental demand at universities, hospitals and research institutes.

Demand for bio equipment and consumables is linked to domestic bio research investment, but market size and growth rates should be checked against statistical agency data.

Among listed bio and pharma companies, Samsung Biologics, Celltrion and Alteogen center on contract manufacturing or new drug and biosimilar development.

Kbio Labs operates a purchase-and-supply distribution model, so its revenue structure and asset mix differ, and the same sector label does not allow the same yardstick. Competitiveness in distribution depends on customer retention, repeat purchases, supplier contract terms and branch sales capacity.

The company's emphasis on repeat purchases and the Daejeon branch in its first-half 2026 explanation reflects this structure. Its operating margin was 1.7% in 2025, leaving a thin profit cushion on revenue, so cost control and customer expansion are the main variables behind profit swings.

On trading, a market data tally showed average trading value below the prior period as of September 7, 2026, which should be read alongside changes in investor interest.

Under KOSDAQ market-cap rules, the administrative issue designation works as a listing requirement, and for this company the market-cap scale within the sector is the direct variable determining its application.

06

Outlook

In its first-half 2026 results explanation, the company said it intends to keep its first-half profit trend in the second half, as reported on August 14, 2026.

In the same explanation, the company said proceeds from the July 2026 capital increase would go toward improving operating efficiency and investing in new businesses. Specifics of the new businesses and their investment scale should be checked in the business description section of the periodic filings.

The first point to check in the Q3 2026 quarterly report is whether the Q2 operating profit continues into Q3. The companion point is whether the KRW 14.4 billion net loss attributable to controlling shareholders, which sits far apart from operating profit, narrows.

Revenue must stabilize after falling to KRW 5.88 billion in Q2 2026, and the Daejeon branch and repeat purchases from existing customers need to support quarterly sales.

Administrative issue designation is tied to the market-cap threshold, so whether market capitalization recovers above that line is directly linked to the exchange's decision. The 2026 annual periodic report is due by March 31, 2027, and the 2025 operating margin of 1.7% will serve as the comparison base.

The effect of new business investment can be checked through changes in the revenue mix and the selling and administrative expense ratio.

07

Valuation

PER
—
PBR
0.3×
ROE
-31.5%
EPS
-₩2,874
BPS
₩7,711
Dividend per share
₩0

On a price-to-book basis, the stock trades in a range below its net asset value. Because the net loss attributable to controlling shareholders has continued over the last four quarters, the price-to-earnings ratio cannot be calculated.

On an annual basis, operating profit and operating cash flow turned positive in 2025, but the net loss attributable to controlling shareholders was a loss in each of the four years from 2022 to 2025.

Of total equity of KRW 102.3 billion, KRW 53.3 billion belongs to controlling shareholders, so the reading of price-to-book depends on whether total equity or controlling-shareholder equity is the base. Dividends contribute effectively nothing to a valuation comparison.

Market capitalization has stayed below the KRW 20.0 billion KOSDAQ designation threshold for more than 25 trading days, a fact tied to listing requirements more than to the share price level itself.

The price-to-earnings ratio becomes calculable depending on a return to profit and the pace at which the controlling-shareholder loss narrows. Comparing the current position with the company's historical price-to-book trading band shows where it sits over time.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-18

08

Bull factors

Operating profit back in the black

Q2 2026 operating profit turned positive at KRW 1.13 billion, up 12,101.4% from a year earlier. First-half 2026 standalone revenue rose 28% year on year to KRW 21.7 billion, which the company attributed to repeat purchases and lower selling and administrative costs, as reported on August 14, 2026. Operating cash flow turning to KRW 8.2 billion in 2025 also supports the operating base.

Revenue growth for two straight years

Revenue reached KRW 76.5 billion in 2024 (up 180.0%) and KRW 87.3 billion in 2025 (up 14.1%), with 2025 the largest year of 2022 to 2025. First-half 2026 cumulative revenue grew year on year, a positive for scale.

Standalone Q2 revenue alone fell sharply from the prior quarter, which should be weighed alongside the bearish points.

Balance sheet headroom and new funding

The debt ratio stood at 16.2% at end-2025, with total liabilities of KRW 16.6 billion. A KRW 2.0 billion capital increase in July 2026 targeting the largest shareholder secured funds for new business investment, as reported on August 14, 2026. A relatively light debt burden gives room for operating funding in the distribution business.

09

Bear factors

Quarterly net loss widens

The net loss attributable to controlling shareholders reached KRW 14.4 billion in Q2 2026, a swing from a KRW 631 million profit in Q1 2026, and the year-on-year loss also widened. Over the last four quarters the total is KRW 14.9 billion.

Because operating profit and the bottom-line loss diverge, earnings strength is hard to judge until the nature of the non-operating items is clear.

Revenue down for two straight quarters

Revenue has declined for two straight quarters from the KRW 28.4 billion peak in Q4 2025. Given the large quarterly swings, first-half cumulative growth does not guarantee the second-half trend.

Designation risk and trading strain

As of November 12, 2026, market capitalization had been below KRW 20.0 billion for 25 consecutive trading days, and the Korea Exchange said the stock could be designated as an administrative issue if the condition continued for five more trading days from November 13.

A market data tally also showed average trading value down 21.14% from the prior period, adding to trading strain.

10

Risk factors

Disclosure history and governance

In a March 2023 notice, the company said accounting violations for 2016 to 2019 had been reflected in its financial statements, and it pledged to cooperate with Korea Exchange procedures to resume trading.

The company said the executives subject to action had all left before 2019 and are unrelated to current management. This disclosure history remains an item to check when assessing earnings reliability.

Listing maintenance requirements

If market capitalization stays below the KRW 20.0 billion threshold for 30 consecutive trading days, the stock may be designated as an administrative issue. Such a designation can affect market reputation and funding conditions.

If the company leans more on capital increases, dilution for existing shareholders also becomes a factor to monitor.

Business concentration and reliance on the largest shareholder

Public disclosures show the largest shareholder holds a stake in the 40% range. The first-half 2026 explanation highlighted the Daejeon branch's role in sales, indicating reliance on specific branch and customer performance. Distribution earnings can swing widely with supply terms and customer concentration.

11

What to watch next

  1. After market close on November 19, 2026

    If market capitalization stays below KRW 20.0 billion for 30 consecutive trading days, the stock becomes eligible for administrative issue designation. The nearest checkpoint is the exchange notice on whether designation occurs and whether market capitalization recovers above the threshold.

  2. Filing date of the Q3 2026 quarterly report (date not yet confirmed)

    The statutory deadline for a quarterly report is 45 days after quarter-end, which for Q3 2026 was November 14, 2026. Alongside the filing date, the checkpoints are the Q3 revenue trend, whether operating profit stays positive, and the composition of the non-operating items that widened the controlling-shareholder loss.

  3. By March 31, 2027

    The 2026 annual periodic report will be compared against 2025 revenue of KRW 87.3 billion and an operating margin of 1.7%. It will also show whether the controlling-shareholder net loss, which has been a loss for four consecutive years, changes direction.

  4. Disclosure of capital increase fund usage (date not yet confirmed)

    Whether the proceeds of the July 2026 capital increase were used for the new business investment and operating efficiency measures the company described can be checked through fund usage disclosures and the notes to the periodic reports.

12

Overall view

Kbio Labs grew revenue to KRW 87.3 billion and operating profit to KRW 1.52 billion in 2025, and it posted an operating profit again in Q2 2026. However, the net loss attributable to controlling shareholders widened to KRW 14.4 billion in the same quarter, and the four-quarter total reaches KRW 14.9 billion.

Revenue has declined in two straight quarters, down to KRW 5.88 billion in Q2 2026, while first-half 2026 cumulative revenue rose year on year according to the company's disclosure as reported.

The balance sheet looks light, with a debt ratio of 16.2% and total equity of KRW 102.3 billion at end-2025, and the July 2026 capital increase added funds.

Market capitalization has been below KRW 20.0 billion for 25 consecutive trading days as of November 12, 2026, which ties directly to the administrative issue requirements.

Bullish factors are the return to operating profit, positive operating cash flow and a low debt ratio, while bearish factors are the wider controlling-shareholder net loss, falling quarterly revenue and designation risk.

The next checkpoints are the exchange's designation decision, the non-operating items in the Q3 2026 quarterly report, and the 2026 annual results. This report is for information only and includes no buy or sell opinion.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 16 more articles and sources
  1. news.nate.com
  2. thevc.kr
  3. butler.works
  4. catch.co.kr
  5. jobkorea.co.kr
  6. saramin.co.kr
  7. kpinfo.kr
  8. kbiocompany.com
  9. topstarnews.net
  10. m.news.nate.com
  11. markets.hankyung.com
  12. judal.co.kr
  13. judal.co.kr
  14. orgo.kr
  15. investing.com
  16. topstarnews.net

Report written 2026-11-19 · Data as of 2026-11-18

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis